FY2026 Earnings Estimate for CAPR Issued By Roth Capital

Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Investment analysts at Roth Capital issued their FY2026 earnings per share (EPS) estimates for shares of Capricor Therapeutics in a report issued on Tuesday, May 20th. Roth Capital analyst B. Pachaiyappan expects that the biotechnology company will post earnings of ($0.72) per share for the year. Roth Capital currently has a "Buy" rating and a $31.00 target price on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.21) per share.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). The business had revenue of $2.73 million during the quarter, compared to the consensus estimate of $3.16 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. During the same quarter in the previous year, the firm posted ($0.31) earnings per share.

Other research analysts have also issued reports about the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $30.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. HC Wainwright reiterated a "buy" rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Monday, March 17th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $35.50.

Capricor Therapeutics Stock Up 6.2%

NASDAQ:CAPR opened at $11.01 on Wednesday. The company has a fifty day moving average of $10.61 and a 200-day moving average of $13.59. The firm has a market capitalization of $502.90 million, a P/E ratio of -10.39 and a beta of 0.85. Capricor Therapeutics has a twelve month low of $3.52 and a twelve month high of $23.40.

Hedge Funds Weigh In On Capricor Therapeutics

A number of large investors have recently modified their holdings of CAPR. Charles Schwab Investment Management Inc. increased its stake in Capricor Therapeutics by 51.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company's stock valued at $1,536,000 after purchasing an additional 37,868 shares in the last quarter. Magnus Financial Group LLC acquired a new position in shares of Capricor Therapeutics during the fourth quarter valued at about $276,000. Swiss National Bank bought a new stake in shares of Capricor Therapeutics during the fourth quarter worth about $930,000. JPMorgan Chase & Co. increased its position in shares of Capricor Therapeutics by 419.5% during the third quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company's stock worth $855,000 after acquiring an additional 45,381 shares in the last quarter. Finally, Alliancebernstein L.P. acquired a new stake in shares of Capricor Therapeutics in the 4th quarter worth about $183,000. 21.68% of the stock is currently owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.